MOGAT1 Antibody, FITC conjugated

Overview of MOGAT1 Antibody, FITC Conjugated

The MOGAT1 Antibody, FITC conjugated (Product Code: CSB-PA836275LC01HU), is a rabbit polyclonal antibody designed to target the Monoacylglycerol O-Acyltransferase 1 (MOGAT1) protein. MOGAT1 is a key enzyme in lipid metabolism, catalyzing the conversion of monoacylglycerol to diacylglycerol, a penultimate step in triacylglycerol synthesis . This antibody is conjugated with fluorescein isothiocyanate (FITC), enabling fluorescence-based detection in applications like immunofluorescence (IF) and flow cytometry (FACS).

Key Features:

• Target: Human MOGAT1 (AA 163-246 region).

• Host: Rabbit polyclonal.

• Conjugate: FITC.

• Applications: Immunofluorescence (IF), Flow Cytometry (FACS).

• Recommended Dilution: 1:50–1:200 (IF), 1:10–1:50 (FACS) .

Structure and Conjugation Details

The antibody is produced by immunizing rabbits with a synthetic peptide corresponding to the C-terminal region of human MOGAT1. The FITC conjugation involves covalent binding of the dye to the antibody’s amino groups, ensuring stable fluorescence while preserving antigen-binding activity .

Conjugation Benefits:

• FITC: Excitation/Emission ≈ 495/519 nm, ideal for green fluorescence detection.

• Polyclonal Design: Ensures broad epitope recognition, enhancing specificity for MOGAT1 in diverse cellular contexts .

Applications in Research

This antibody is primarily used for studying MOGAT1’s role in lipid metabolism and metabolic disorders. Key applications include:

Immunofluorescence (IF):

• Visualizing MOGAT1 localization in hepatocytes or adipose tissue.

• Co-staining with lipid droplet markers (e.g., Nile Red) to study lipid storage .

Flow Cytometry (FACS):

• Quantifying MOGAT1 expression in primary hepatocytes or immortalized cell lines.

• Analyzing MOGAT1 dynamics during metabolic stress (e.g., high-fat diet models) .

Research Findings and Context

While direct studies using the FITC-conjugated MOGAT1 antibody are not explicitly cited, its utility aligns with broader MOGAT1 research:

• Hepatic Steatosis: MOGAT1 inhibition via antisense oligonucleotides (ASOs) reduces hepatic triglyceride content in diet-induced obesity models .

• Insulin Sensitivity: Overexpression of MOGAT1 in hepatocytes increases liver triacylglycerol (TAG) without inducing insulin resistance, suggesting complex metabolic regulation .

• Off-Target Effects: Some MOGAT1-targeting ASOs activate interferon signaling, highlighting the need for precise antibody validation in metabolic studies .